BIA-BCL and BIA--SCC

Q: Breast implant-associated squamous cell carcinoma (BIA-SCC) and breast implant-associated B-cell lymphoma (BIA-BCL) are usually benign diseases. 

A) True

B) False

Answer: B

BIA-BCL and BIA-SCC, if they occur, are aggressive tumors, which may require surgical en bloc excision of the implant, capsule, and tumor, followed by chemotherapy as well as radiation therapy.

BIA-BCL seems to be more responsive to chemotherapy, whereas BIA-SCC is found to be less responsive to chemotherapy.

They can occur with any type of implant and typically develop late, with a mean time of around 22-23 years. BIA-BCL usually presents as erythema and a periprosthetic effusion, while BIA-SCC presents as a late-onset seroma or mass.

#oncology

References:

1. Goldberg MT, Llaneras J, Willson TD, et al. Squamous Cell Carcinoma Arising in Breast Implant Capsules. Ann Plast Surg 2021; 86:268.

2. Buchanan PJ, Chopra VK, Walker KL, et al. Primary Squamous Cell Carcinoma Arising From a Breast Implant Capsule: A Case Report and Review of the Literature. Aesthet Surg J 2018; 38.

3. Fracol ME, Rodriguez MM, Clemens MW. A Spectrum of Disease: Breast Implant-Associated Anaplastic Large Cell Lymphoma, Atypicals, and Other Implant Associations. Clin Plast Surg 2023; 50:249.

American Society of Plastic Surgeons statement on breast cancer-associated squamous cell carcinoma. 09/08/2022. https://www.plasticsurgery.org/for-medical-professionals/publications/psn-extra/news/asps-statement-on-breast-implant-associated-squamous-cell-carcinoma (last accessed on October 2, 2025.